RT Journal Article
SR Electronic
T1 SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.07.21261578
DO 10.1101/2021.08.07.21261578
A1 Chemaitelly, Hiam
A1 AlMukdad, Sawsan
A1 Joy, Jobin Paravila
A1 Ayoub, Houssein H.
A1 Yassine, Hadi M.
A1 Benslimane, Fatiha M.
A1 Al Khatib, Hebah A.
A1 Tang, Patrick
A1 Hasan, Mohammad R.
A1 Coyle, Peter
A1 Al Kanaani, Zaina
A1 Al Kuwari, Einas
A1 Jeremijenko, Andrew
A1 Kaleeckal, Anvar Hassan
A1 Latif, Ali Nizar
A1 Shaik, Riyazuddin Mohammad
A1 Abdul Rahim, Hanan F.
A1 Nasrallah, Gheyath K.
A1 Al Kuwari, Mohamed Ghaith
A1 Butt, Adeel A.
A1 Al Romaihi, Hamad Eid
A1 Al-Thani, Mohamed H.
A1 Alkadi, Mohamad M.
A1 Ali, Omar
A1 Al-Maslamani, Muna
A1 Bertollini, Roberto
A1 Al Malki, Hassan
A1 Almaslamani, Yousuf
A1 Abu-Raddad, Laith J.
A1 Al Khal, Abdullatif
YR 2021
UL http://medrxiv.org/content/early/2021/08/09/2021.08.07.21261578.abstract
AB COVID-19 vaccine protection against infection in immunosuppressed solid organ transplant recipients is unknown but possibly weak with the low proportion of these patients mounting a robust humoral and cellular immune response after vaccination. Using a retrospective cohort study design with cross-over, we assessed vaccine effectiveness among 782 kidney transplant recipients registered at Hamad Medical Corporation, the national public healthcare provider in Qatar, where the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines have been used in the national immunization campaign. Vaccine effectiveness against any SARS-CoV-2 infection was estimated at 46.6% (95% CI: 0.0-73.7%) ≥14 days after the second dose, 66.0% (95% CI: 21.3-85.3%) ≥42 days after the second dose, and 73.9% (95% CI: 33.0-89.9%) ≥56 days after the second dose. Vaccine effectiveness against any severe, critical, or fatal COVID-19 disease was estimated at 72.3% (95% CI: 0.0-90.9%) ≥14 days after the second dose, 85.0% (95% CI: 35.7-96.5%) ≥42 days after the second dose, and 83.8% (95% CI: 31.3-96.2%) ≥56 days after the second dose. Most vaccine breakthrough infections occurred in the first few weeks after receiving the first and/or second dose. Vaccine effectiveness reached considerable levels in kidney transplant recipients, but vaccine protection mounted slowly and did not reach a high level until several weeks after the second dose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support from the Biomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core, and the Genomics Core, all at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health and Hamad Medical Corporation. The authors are also grateful for support from the Qatar Genome Programme for supporting the viral genome sequencing. Statements made herein are solely the responsibility of the authors. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with waiver of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.